ArticlePlastic and reconstructive surgery. Global open2025
Antiemetic Effect of Pregabalin in Postbariatric Breast Reconstructions: Randomized, Double-blind Study.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative nausea and vomiting (PONV) are common complications after general anesthesia. Pregabalin may reduce its incidence. The primary study outcome was to evaluate the antiemetic effect of pregabalin within the first 24 hours postoperatively. Methods: This randomized, double-blind study included 52 female patients aged between 18 and 64 years, classified as American Society of Anesthesiologists physical status I or II, who underwent postbariatric breast reconstruction under general anesthesia. The patients were randomly divided into 2 groups. The control group received a placebo, and the pregabalin group received 75 mg of pregabalin 2 hours before surgery and another 75 mg 12 hours later. The primary outcome evaluated was the incidence of PONV during the first 24 hours postoperatively. Secondary outcomes were pain during the first 24 hours, the opioid-sparing effect of pregabalin, the need for rescue doses of antiemetic or analgesic drugs within the first 24 hours, the development of chronic postoperative pain, and adverse events in the first 24 hours. Results: The groups were homogeneous in clinical and treatment variables. There was no significant difference in the incidence of nausea ( Conclusions: The administration of pregabalin during the first 24 hours after surgery did not significantly reduce PONV in patients undergoing postbariatric breast reconstruction under general anesthesia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.